Clinical trial
Comparing FTC and Lamivudine in HIV-Infected Patients on a Stable Anti-HIV Drug…
NCT00002416 · Triangle Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00002416 |
|---|---|
| Title | Comparing FTC and Lamivudine in HIV-Infected Patients on a Stable Anti-HIV Drug Combination |
| Official title | A Randomized, Open-Label Equivalence Study of FTC Versus Lamivudine in Patients on a Stable Triple Antiretroviral Therapy Regimen Containing Lamivudine, Stavudine or Zidovudine, and a Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor |
| Lead sponsor | Triangle Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Emtricitabine, Lamivudine |
| Enrollment | 390 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: